Trinity Biotech plc has received full regulatory approval to begin upstream manufacturing activities for its Uni-Gold™ HIV rapid test under a new offshored and outsourced production model. This approval is a key milestone in the company’s Comprehensive Transformation Plan and is expected to expand gross margins, improve working capital efficiency, and enhance long-term scalability. With this approval, Trinity Biotech can now transition to a more cost-efficient offshore manufacturing platform for the Uni-Gold™ HIV test, supporting future demand growth. This approval follows WHO authorization for Uni-Gold™ HIV in November 2025. CEO John Gillard highlighted the significance of this approval in realizing the potential of the new manufacturing model.

Read more at GlobeNewswire: Trinity Biotech Secures Regulatory Approval for